Please ensure Javascript is enabled for purposes of website accessibility

Why DBV Technologies Shares Soared Today

By Brian Feroldi - Updated Apr 4, 2019 at 5:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Traders cheered after the company announced the pricing details of a stock offering.

What happened

In response to revealing the pricing information of its recently announced common-stock offering, DBV Technologies (DBVT -4.70%), a clinical-stage biotech focused on food allergies, saw its stock rise 11% on Thursday. 

So what

Here are the details from the deal:

  • The company is selling 5.2 million ordinary shares and will raise $70.4 million. The shares are being sold as American depositary shares (ADSs), and as ordinary shares in Europe. Each ADS represents the right to receive one-half of one ordinary share.
  • A total of 1.66 million ordinary shares will be sold in the form of 3.33 million ADSs in the United States, Canada, and certain other countries outside Europe. The price is $6.75 per ADS based on current exchange rates. 
  • 3.55 million ordinary shares will be sold in Europe at a public offering price of 12.02 euros per share.
  • The underwriters of the deal have been granted the option to purchase up to 1.56 million ADSs as well. 
  • The company plans on using the proceeds to fund the continued development of its pipeline and prepare for the commercialization of the Viaskin Peanut allergy treatment.
  • As part of the deal, the company's directors and executive officers have agreed to enter into a lockup period during which they cannot sell shares for 90 days.

Traders appear to be excited about the terms of this capital raise.

Man with money in his hands

Image source: Getty Images.

Now what

It isn't often that a company raises capital from a common-stock offering and its share price goes up. That likely indicates that Wall Street was assuming the pricing details of the deal were going to be far more dilutive than they are.

Short-term movements aside, the next big event for investors to look forward to is the resubmission of Viaskin Peanut to the Food and Drug Administration. The company expects that to happen in the third quarter of this year.

Will Viaskin Peanut finally go on to win regulatory approval and turn into a commercial success? Only time will tell. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DBV Technologies S.A. Stock Quote
DBV Technologies S.A.
$1.42 (-4.70%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.